These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27847125)

  • 1. Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases.
    Mandalà M; Galli F; Cattaneo L; Merelli B; Rulli E; Ribero S; Quaglino P; De Giorgi V; Pigozzo J; Sileni VC; Chirco A; Ferrucci PF; Occelli M; Imberti G; Piazzalunga D; Massi D; Tondini C; Queirolo P;
    J Am Acad Dermatol; 2017 Feb; 76(2):264-273.e2. PubMed ID: 27847125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
    Mandalà M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
    Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective, multicenter analysis of the predictive value of mitotic rate for sentinel lymph node (SLN) positivity in thin melanomas.
    Wat H; Senthilselvan A; Salopek TG
    J Am Acad Dermatol; 2016 Jan; 74(1):94-101. PubMed ID: 26542815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival analysis and sentinel lymph node status in thin cutaneous melanoma: A multicenter observational study.
    Tejera-Vaquerizo A; Ribero S; Puig S; Boada A; Paradela S; Moreno-Ramírez D; Cañueto J; de Unamuno B; Brinca A; Descalzo-Gallego MA; Osella-Abate S; Cassoni P; Carrera C; Vidal-Sicart S; Bennássar A; Rull R; Alos L; Requena C; Bolumar I; Traves V; Pla Á; Fernández-Orland A; Jaka A; Fernández-Figueres MT; Hilari JM; Giménez-Xavier P; Vieira R; Botella-Estrada R; Román-Curto C; Ferrándiz L; Iglesias-Pena N; Ferrándiz C; Malvehy J; Quaglino P; Nagore E;
    Cancer Med; 2019 Aug; 8(9):4235-4244. PubMed ID: 31215168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is mitotic rate still useful in the management of patients with thin melanoma?
    Tejera-Vaquerizo A; Pérez-Cabello G; Marínez-Leborans L; Gallego E; Oliver-Martínez V; Martín-Cuevas P; Arias-Santiago S; Aneiros-Fernández J; Herrera-Acosta E; Traves V; Herrera-Ceballos E; Nagore E
    J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):2025-2029. PubMed ID: 28750139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of sentinel lymph node positivity in thin melanoma using the National Cancer Database.
    Conic RRZ; Ko J; Damiani G; Funchain P; Knackstedt T; Vij A; Vidimos A; Gastman BR
    J Am Acad Dermatol; 2019 Feb; 80(2):441-447. PubMed ID: 30240775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Mitotic Rate Predicts Sentinel Lymph Node Involvement in Thin Melanomas.
    Skochdopole AJ; Kutlu OC; Engelhardt KE; Lancaster WP; Abbott AM; Camp ER
    J Surg Res; 2020 Dec; 256():198-205. PubMed ID: 32711176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.
    Statius Muller MG; van Leeuwen PA; de Lange-De Klerk ES; van Diest PJ; Pijpers R; Ferwerda CC; Vuylsteke RJ; Meijer S
    Cancer; 2001 Jun; 91(12):2401-8. PubMed ID: 11413531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
    Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR
    Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sentinel lymph node status affects long-term survival in patients with intermediate-thickness melanoma.
    G Lben K; Berberoğlu U; Altınyollar H; Kınaş V; Turanlı S
    J Cancer Res Ther; 2016; 12(2):840-4. PubMed ID: 27461661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma.
    Han D; Zager JS; Shyr Y; Chen H; Berry LD; Iyengar S; Djulbegovic M; Weber JL; Marzban SS; Sondak VK; Messina JL; Vetto JT; White RL; Pockaj B; Mozzillo N; Charney KJ; Avisar E; Krouse R; Kashani-Sabet M; Leong SP
    J Clin Oncol; 2013 Dec; 31(35):4387-93. PubMed ID: 24190111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor mitotic rate added to the equation: melanoma prognostic factors changed? : a single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients.
    Speijers MJ; Bastiaannet E; Sloot S; Suurmeijer AJ; Hoekstra HJ
    Ann Surg Oncol; 2015 Sep; 22(9):2978-87. PubMed ID: 25605514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of mitotic rate reporting in melanoma.
    Burton AL; Egger ME; Gilbert JE; Stromberg AJ; Hagendoorn L; Martin RC; Scoggins CR; McMasters KM; Callender GG
    Am J Surg; 2012 Dec; 204(6):969-74; discussion 974-5. PubMed ID: 23036603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Role of Multiple Lymphatic Basin Drainage in Sentinel Lymph Node-Negative Trunk Melanoma Patients: A Multicenter Study from the Italian Melanoma Intergroup.
    Ribero S; Osella-Abate S; Pasquali S; Rossi CR; Borgognoni L; Piazzalunga D; Solari N; Schiavon M; Brandani P; Ansaloni L; Ponte E; Silan F; Sommariva A; Bellucci F; Macripò G; Quaglino P
    Ann Surg Oncol; 2016 May; 23(5):1708-15. PubMed ID: 26597362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
    Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
    Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma.
    Kruper LL; Spitz FR; Czerniecki BJ; Fraker DL; Blackwood-Chirchir A; Ming ME; Elder DE; Elenitsas R; Guerry D; Gimotty PA
    Cancer; 2006 Nov; 107(10):2436-45. PubMed ID: 17058288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of sentinel lymph node involvement in a modern, large series of desmoplastic melanoma.
    Egger ME; Huber KM; Dunki-Jacobs EM; Quillo AR; Scoggins CR; Martin RC; Stromberg AJ; McMasters KM; Callender GG
    J Am Coll Surg; 2013 Jul; 217(1):37-44; discussion 44-5. PubMed ID: 23791271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors in melanoma patients with tumor-negative sentinel lymph nodes.
    Egger ME; Bhutiani N; Farmer RW; Stromberg AJ; Martin RC; Quillo AR; McMasters KM; Scoggins CR
    Surgery; 2016 May; 159(5):1412-21. PubMed ID: 26775577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma?
    Gajdos C; Griffith KA; Wong SL; Johnson TM; Chang AE; Cimmino VM; Lowe L; Bradford CR; Rees RS; Sabel MS
    Cancer; 2009 Dec; 115(24):5752-60. PubMed ID: 19827151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitotic rate for thin melanomas: should a single mitotic figure warrant a sentinel lymph node biopsy?
    Kirkland EB; Zitelli JA
    Dermatol Surg; 2014 Sep; 40(9):937-45. PubMed ID: 25072127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.